Big effect
A double-blind trial found that 600 mg of N-acetyl cysteine taken twice daily slashed the rate of a dangerous platelet-drop from 41.6% to 16.8% in critically ill patients on linezolid — though the results come from a single study in a very specific, sick population and need replication before they apply more broadly.
This is one of the first rigorous trials to show NAC can prevent a serious side effect of a common antibiotic, but the finding is so novel that it should be treated as promising preliminary evidence, not a settled benefit for everyone.
In critically ill patients given the antibiotic linezolid, adding intravenous N-acetyl cysteine (600 mg every 12 hours) reduced the number of people who developed dangerously low platelet counts from about 42% to about 17%. The same study also found that NAC led to higher platelet counts overall, fewer patients needing platelet transfusions, and fewer patients having to stop linezolid — all statistically significant benefits. However, because this is the first major trial on this specific pairing and studied only a narrow group of very sick hospital patients, the results may not apply to healthier individuals or those taking NAC orally.
Where this fits in the evidence
This is among the first studies we've indexed on N-Acetyl Cysteine for Reduced Thrombocytopenia — treat it as an early signal until more research accumulates.
The study
- Randomized Controlled Trial (RCT)
- 2026-03
- Environmental toxicology and pharmacology
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.